Artiva Biotherapeutics is a biotech startup that operates in the field of immunotherapy, specifically focusing on the development of cell therapies for cancer and autoimmune diseases. The company's primary mission is to create effective, safe, and accessible treatments for patients suffering from these devastating conditions.

Artiva's business model revolves around the production of off-the-shelf, allogeneic NK cell therapies. Allogeneic means the cells are harvested from a donor, not the patient, which allows for mass production and reduces the time and cost associated with patient-specific manufacturing. This approach aims to make cell therapy more accessible to a larger number of patients.

The company's flagship product is AlloNK®, a non-genetically modified NK cell therapy. It is designed to enhance the activity of monoclonal antibodies or NK cell engagers, which are proteins designed to bind to specific targets on cancer cells. AlloNK® is currently undergoing clinical trials for the treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and Non-Hodgkin Lymphoma. It is also being tested in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.

Artiva generates revenue through the development, clinical testing, and eventual commercialization of its cell therapies. The company's target market includes patients with autoimmune diseases and various forms of cancer, as well as healthcare providers and institutions that treat these conditions.

Keywords: Immunotherapy, Cell Therapy, Cancer Treatment, Autoimmune Disease Treatment, Allogeneic NK Cell Therapies, Biotech Startup, Clinical Trials, Monoclonal Antibodies, NK Cell Engagers, Systemic Lupus Erythematosus.